|
注册号: Registration number: |
ChiCTR2000029516 |
|
最近更新日期: Date of Last Refreshed on: |
2020-02-03 10:44:51 |
|
注册时间: Date of Registration: |
2020-02-03 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
吴庆尧医师:该研究尚未获得伦理委员会批准。请于批准后再开始纳入参试者,并与我们联系上传批件。同时,请尽快上传研究计划书、知情同意书模板。 基于放射组学的直肠癌微卫星不稳定性预测平台的建立临床应用 |
|
Public title: |
Establishment and clinical application value of an automatic prediction platform for rectal cancer MSI based on radiology |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
基于放射组学的直肠癌微卫星不稳定性预测平台的建立临床应用 |
|
Scientific title: |
Establishment and clinical application value of an automatic prediction platform for rectal cancer MSI based on radiology |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
吴庆尧 |
研究负责人: |
卢云 |
|
Applicant: |
Wu Qingyao |
Study leader: |
Lu Yun |
|
申请注册联系人电话: Applicant telephone: |
+86 18663920197 |
研究负责人电话:
Study leader's |
+86 18661802231 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
1257580502@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
cloudylucn@126.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
中国山东省青岛市黄岛区五台山路1677号 |
研究负责人通讯地址: |
中国山东省青岛市黄岛区五台山路1677号 |
|
Applicant address: |
1677 Wutaishan Road, Huangdao District, Qingdao, Shandong, China |
Study leader's address: |
1677 Wutaishan Road, Huangdao District, Qingdao, Shandong, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
青岛大学附属医院 |
||
|
Applicant's institution: |
The Affiliated Hospital of Qingdao University |
||
|
研究负责人所在单位: |
青岛大学附属医院 |
||
|
Affiliation of the Leader: |
The Affiliated Hospital of Qingdao University |
||
|
是否获伦理委员会批准: |
否 |
||
|
Approved by ethic committee: |
No |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
伦理委员会批件附件: Approved file of Ethical Committee: |
||
|
批准本研究的伦理委员会名称: |
|
||
|
Name of the ethic committee: |
|
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2013-08-26 00:00:00 | ||
|
伦理委员会联系人: |
|
||
|
Contact Name of the ethic committee: |
|
||
|
伦理委员会联系地址: |
|
||
|
Contact Address of the ethic committee: |
|
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
||
|
研究实施负责(组长)单位: |
青岛大学附属医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The Affiliated Hospital of Qingdao University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
中国山东省青岛市黄岛区五台山路1677号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
1677 Wutaishan Road, Huangdao District, Qingdao, Shandong, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
青岛大学数字医学与计算机辅助手术研究院 |
||||||||||||||||||||||
|
Source(s) of funding: |
Institute of digital medicine and computer aided surgery, Qiingdao University |
||||||||||||||||||||||
|
研究疾病: |
直肠癌 |
||||||||||||||||||||||
|
Target disease: |
rectal cancer |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
诊断试验 |
||||||||||||||||||||||
|
Study type: |
Diagnostic test |
||||||||||||||||||||||
|
研究所处阶段: |
探索性研究/预试验 | ||||||||||||||||||||||
|
Study phase: |
0 |
||||||||||||||||||||||
|
研究设计: |
连续入组 |
||||||||||||||||||||||
|
Study design: |
Sequential |
||||||||||||||||||||||
|
研究目的: |
利用现有的放射组学软件及算法,将直肠癌病人的MRI图像,临床检验及病理结果输入系统,通过深度学习多次迭代学习及修正,发现各个因素之间的关联性,从而建立起基于放射组学的直肠癌微卫星不稳定性的自动预测系统。并经过验证组的验证,验证平台的准确性及其临床应用价值。 |
||||||||||||||||||||||
|
Objectives of Study: |
Using existing set of radiology analysis, algorithm and software technology, we input imaging dataclinically relevant inspection and test results of rectal cancer patients into program. And through training and learning for many times. We established the platform to predict the MSI of rectal cancer patients , and through the set of data validation, we evaluate the accuracy of the prediction platform and the clinical application value. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
1. 肿瘤发生其他部位转移; |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Metastasis to other parts of the tumor; |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2020-02-24 00:00:00至 To 2020-09-01 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2020-03-01 00:00:00 至 To 2020-06-01 00:00:00 |
|
诊断试验: Diagnostic Tests: |
|
||||||||||||||||||||||||||||
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
不适用 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
N/A |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
未说明 |
|
Blinding: |
Not stated |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
Resman www.medresman.org.cn. |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Resman www.medresman.org.cn. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
电子采集和管理系统 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Electronic Data Capture, EDC |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |